Skip to main content

 Scientific publications

Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach.

Authors : Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Larsimont D, Park M, Rothé F, Stagg J, Sotiriou C
Year : 2019
Journal : J Natl Cancer Inst

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors : Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2019
Journal : JCI Insight
Volume : 5

Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis.

Authors : Allard B, Cousineau I, Allard D, Buisseret L, Pommey S, Chrobak P, Stagg J
Year : 2019
Journal : Oncoimmunology
Volume : 8
Pages : 1601481

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

Authors : Nederlof I, De Bortoli D, Bareche Y, Nguyen B, de Maaker M, Hooijer GKJ, Buisseret L, Kok M, Smid M, Van den Eynden GGGM, Brinkman AB, Hudecek J, Koster J, Sotiriou C, Larsimont D, Martens JWM, Van de Vijver MJ, Horlings HM, Salgado R, Biganzoli E, Desmedt C
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 151

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Authors : Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J
Year : 2018
Journal : Ann Oncol
Volume : 29(4)
Pages : 1056-62

Immuno-oncology-101: overview of major concepts and translational perspectives.

Authors : Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L
Year : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 1-11

Immune Infiltration in Invasive Lobular Breast Cancer.

Authors : Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C
Year : 2018
Journal : J Natl Cancer Inst
Volume : 110(7)
Pages : 768-776

Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer.

Authors : Garaud S, Zayakin P, Buisseret L, Rulle U, Silina K, de Wind A, Van den Eyden G, Larsimont D, Willard-Gallo K
Year : 2018
Journal : Front Immunol
Volume : 9
Pages : 2660

PolyI:C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors.

Authors : Charlebois R, Allard B, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J
Year : 2017
Journal : Cancer Res
Volume : 77(2)
Pages : 312-9

Targeting immune checkpoints in breast cancer: an update of early results.

Authors : Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L
Year : 2017
Journal : ESMO Open
Volume : 2
Pages : e000255

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Authors : Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J
Year : 2017
Journal : Cancer Res
Volume : 77(20)
Pages : 5652-5663

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Authors : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Year : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

Authors : Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M
Year : 2017
Journal : Cancer Treat Rev
Volume : 57
Pages : 8-15

CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.

Authors : Gu-Trantien C, Migliori E, Buisseret L, de Wind A, Brohée S, Garaud S, Noël G, Dang Chi VL, Lodewyckx JN, Naveaux C, Duvillier H, Goriely S, Larsimont D, Willard-Gallo K
Year : 2017
Journal : JCI Insight
Volume : 2

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Authors : Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K
Year : 2016
Journal : Oncoimmunology
Volume : 6
Pages : e1257452

Belgian Society of Medical oncology (BSMO - task force on breast cancer survivorship)

Authors : de Azambuja E, Azim HA, Buisseret L, Langenaeken C, Tkint de Roodenbeke D
Year : 2014
Journal : Belgian J Medical Oncology
Volume : 7(5)
Pages : 142-155

A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes.

Authors : Garaud S, Gu-Trantien C, Lodewyckx JN, Boisson A, De Silva P, Buisseret L, Migliori E, Libin M, Naveaux C, Duvillier H, Willard-Gallo K
Year : 2014
Journal : J Vis Exp
Volume : null(94)